Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With ...

Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Jay Bradner, Murdo Gordon ...

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and ...

Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of ...

The stock market is divided, with the Nasdaq and S&P 500 breaking support but many sectors thriving. Google and Amazon AI ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco for the industry's biggest investor event of the year. Monday, we'll be ...

Under its former childhood vaccine schedule, the U.S. Centers for Disease Control and Prevention recommended that kids get 12 different vaccines protecting against 16 diseases before age 10. It didn’t ...

The arrival of the Wegovy pill (semaglutide), the first oral GLP-1 drug approved to treat obesity, means freedom of choice: Adults who are looking to lose weight and have at least one weight-related ...

It’s hard to think of vaccination without associating it with a sharp jab in the arm. But there are other, more gentle ways of activating the immune system, such as administering vaccines via the nose ...